drugset / Trial / NCT04898088

A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients

NCT04898088 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Our aim in this study is to determine the positive effect of stem cell therapy applied on critically ill patients with coronavirus infection on DNA repair genes. Patients diagnosed with COVID-19 infection are divided into two equal (n:30) groups. Group-1(n/15): Patients in critically ill condition receiving conventional therapy, Group-2 (n/15): Patients in critically ill condition receiving conventional therapy and systemically transplanted MSCs. The DNA repair pathway will be examined as 11 genes in 5 different parts. Investigated parameters: 1. Base excision repair 2. Nucleotide excision repair 3. Recombinational repair 4. Mismatch repair 5. Direct reversal Investigated parameters: broad biochemical analysis, apoptosis, clinical outcome, and mortality rates.

Timeline

Start
2020-01-01
Primary completion
2020-08-30
Completion
2020-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesenchymal Stem Cells Transplantation Cell therapy — Intravenous

Indications